Amorphigenin inhibits Osteoclast differentiation by suppressing c-Fos and nuclear factor of activated T cells.
Among the several rotenoids, amorphigenin is isolated from the leaves of Amopha Fruticosa and it is known that has anti-proliferative effects and anti-cnacer effects in many cell types. The main aim of this study was to investigate the effects of amorphigenin on osteoclast differentiation in vitro and on LPS treated inflammatory bone loss model in vivo. We show here that amorphigenin inhibited RANKL-induced osteoclast differentiation from bone marrow macrophages in a dose dependent manner without cellular toxicity. Anti-osteoclastogenic properties of amorphigenin were based on a down-regulation of c-fos and NFATc1. Amorphigenin markedly inhibited RANKL-induced p38 and NF-κB pathways, but other pathways were not affected. Micro-CT analysis of the femurs showed that amorphigenin protected the LPS-induced bone loss. We concluded that amorphigenin can prevent inflammation-induced bone loss. Thus we expect that amorphigenin could be a treatment option for bone erosion caused by inflammation.
Department of Orthopedic Surgery, School of Medicine, Wonkwang University, Iksan, Korea.
Bong Gyu
BG
Kim
Han Bok
HB
Kwak
Eun-Yong
EY
Choi
Hun Soo
HS
Kim
Myung Hee
MH
Kim
Seong Hwan
SH
Kim
Min-Kyu
MK
Choi
Churl Hong
CH
Chun
Jaemin
J
Oh
Jeong-Joong
JJ
Kim
J Ethnopharmacol. 2007 Sep 5;113(2):191-8
17646068
Front Biosci. 2007 Jan 01;12:2519-29
17127260
J Periodontol. 2005 Nov;76(11 Suppl):2066-74
16277578
Oncology (Williston Park). 2001 Sep;15(9):1177-85, 1189-90; discussion 1190-4
11589065
Bone. 2002 May;30(5 Suppl):75S-79S
12008163
Science. 2000 Sep 1;289(5484):1504-8
10968780
J Mol Med (Berl). 2005 Mar;83(3):170-9
15776286
J Exp Med. 2003 May 19;197(10):1303-10
12743173
J Cancer Res Clin Oncol. 2010 Aug;136(8):1117-24
20508948
Annu Rev Immunol. 2006;24:33-63
16551243
Nature. 2003 May 15;423(6937):337-42
12748652
Science. 2000 Sep 1;289(5484):1508-14
10968781
Dev Cell. 2002 Dec;3(6):889-901
12479813
Biochim Biophys Acta. 2009 Aug;1792(8):757-65
19465118
Bone. 2010 Mar;46(3):724-31
19900598
Nat Rev Immunol. 2007 Apr;7(4):292-304
17380158
Eksp Med Morfol. 1985;24(2):50-4
4065006
Exp Mol Med. 2006 Jun 30;38(3):256-64
16819284
Nat Rev Genet. 2003 Aug;4(8):638-49
12897775
N Engl J Med. 1998 Jul 16;339(3):202; author reply 203
9669921
J Bone Miner Res. 1999 Oct;14 Suppl 2:53-65
10510215
Mol Endocrinol. 2008 Jan;22(1):176-85
17885208
Clin Geriatr Med. 2003 May;19(2):395-414
12916293
Biochem Cell Biol. 1998;76(6):911-22
10392705
Int Immunopharmacol. 2007 Dec 5;7(12):1507-16
17920527
Arthritis Rheum. 2000 Feb;43(2):259-69
10693864
J Immunol. 2004 May 15;172(10):5940-7
15128775
Eur J Pharmacol. 2008 Feb 2;580(1-2):70-9
18083161